Literature DB >> 19298913

The immune system and chronic heart failure: is the heart in control?

James E Fildes1, Steven M Shaw, Nizar Yonan, Simon G Williams.   

Abstract

Despite current treatment options, the clinical course of patients with chronic heart failure is notoriously difficult to predict. Among those with similar etiologies, ejection fractions, and patient demographics, our understanding of why such variations in outcomes exist remains limited. Evidence that has been progressively gathered implicates an important role of the immune system in the propagation of heart failure. This has been derived mainly from observations that cytokines are progressively elevated in patients with poor outcomes. However, attempts at introducing various immunomodulatory therapies as a new treatment strategy have been largely unsuccessful to date. This possibly reflects a failure in recognizing the complexity of the immune system's role in chronic heart failure, which has led to an oversimplified approach to treatment. This review critically analyzes the immune treatments attempted to date and hypothesizes what is required to develop a successful future treatment strategy.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19298913     DOI: 10.1016/j.jacc.2008.11.046

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  29 in total

1.  The role of nitric oxide in regulation of leukocyte migration into the heart tissue in vitro.

Authors:  A A Petenkova; R I Kovalenko; A D Nozdrachev
Journal:  Dokl Biol Sci       Date:  2016-01-05

2.  The Guanine Nucleotide Exchange Factor Brx: A Link between Osmotic Stress, Inflammation and Organ Physiology and Pathophysiology.

Authors:  Tomoshige Kino; James H Segars; George P Chrousos
Journal:  Expert Rev Endocrinol Metab       Date:  2010-07-01

Review 3.  Novel therapeutic targets for the treatment of heart failure.

Authors:  Juan Tamargo; José López-Sendón
Journal:  Nat Rev Drug Discov       Date:  2011-06-24       Impact factor: 84.694

4.  Usefulness of cell-mediated immune function in risk stratification for patients with advanced heart failure.

Authors:  Vijaiganesh Nagarajan; Adrian V Hernandez; Clay A Cauthen; Randall C Starling; W H Wilson Tang
Journal:  Am Heart J       Date:  2016-09-30       Impact factor: 4.749

5.  Baseline Immunoglobulin E Levels as a Marker of Doxorubicin- and Trastuzumab-Associated Cardiac Dysfunction.

Authors:  Lynn A Beer; Andrew V Kossenkov; Qin Liu; Eline Luning Prak; Susan Domchek; David W Speicher; Bonnie Ky
Journal:  Circ Res       Date:  2016-08-31       Impact factor: 17.367

Review 6.  TNFα in myocardial ischemia/reperfusion, remodeling and heart failure.

Authors:  Petra Kleinbongard; Rainer Schulz; Gerd Heusch
Journal:  Heart Fail Rev       Date:  2011-01       Impact factor: 4.214

7.  Attenuation of monocyte chemotaxis--a novel anti-inflammatory mechanism of action for the cardio-protective hormone B-type natriuretic peptide.

Authors:  Nadezhda Glezeva; Patrick Collier; Victor Voon; Mark Ledwidge; Kenneth McDonald; Chris Watson; John Baugh
Journal:  J Cardiovasc Transl Res       Date:  2013-04-27       Impact factor: 4.132

Review 8.  Intermediate filaments in cardiomyopathy.

Authors:  Mary Tsikitis; Zoi Galata; Manolis Mavroidis; Stelios Psarras; Yassemi Capetanaki
Journal:  Biophys Rev       Date:  2018-07-19

9.  Plasma osteoprotegerin, its correlates, and risk of heart failure: a prospective cohort study.

Authors:  Romina di Giuseppe; Ronald Biemann; Janine Wirth; Juliane Menzel; Berend Isermann; Gabriele I Stangl; Andreas Fritsche; Heiner Boeing; Matthias B Schulze; Cornelia Weikert
Journal:  Eur J Epidemiol       Date:  2016-06-15       Impact factor: 8.082

10.  The Cardiomyocyte as a Source of Cytokines in Cardiac Injury.

Authors:  Toshinori Aoyagi; Takashi Matsui
Journal:  J Cell Sci Ther       Date:  2011-12-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.